Modality
ADC
MOA
JAK1i
Target
BCMA
Pathway
T-cell
NASHPsA
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
May 2019
→ May 2028
Phase 2Current
NCT04532953
2,591 pts·NASH
2019-05→2025-01·Not yet recruiting
NCT08671147
2,955 pts·PsA
2020-02→2028-05·Terminated
5,546 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-011.2y agoPh2 Data· NASH
2028-05-022.1y awayPh2 Data· PsA
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Not yet…
P2
Termina…
Catalysts
Ph2 Data
2025-01-01 · 1.2y ago
NASH
Ph2 Data
2028-05-02 · 2.1y away
PsA
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04532953 | Phase 2 | NASH | Not yet recr... | 2591 | LiverFat |
| NCT08671147 | Phase 2 | PsA | Terminated | 2955 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |